Patent Law and Theory
Show Less

Patent Law and Theory

A Handbook of Contemporary Research

Edited by Toshiko Takenka

This major Handbook provides a comprehensive research source for patent protection in three major jurisdictions: the United States, Europe and Japan. Leading patent scholars and practitioners join together to give an innovative comparative analysis both of fundamental issues such as patentability, examination procedure and the scope of patent protection, and current issues such as patent protection for industry standards, computer software and business methods. Keeping in mind the important goal of world harmonization, the contributing authors challenge current systems and propose necessary changes for promoting innovation.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 19: Enabling Research or Unfair Competition? De Jure and De Facto Research Use Exceptions in Major Technology Countries

Sean O’Connor


Sean O’Connor* Introduction To start with the basics, the unauthorized making, using, or selling of patented inventions is normally an infringement of exclusive patent rights. Further, in many countries, the unauthorized import of products embodying the patented invention, or resulting from the patented process, is also an infringement of exclusive patent rights. Thus, absent an exception, all research which either experiments on or with patented inventions – including both non-commercial research by universities or non-profits and product-oriented research and development (R&D) by commercial firms – constitutes patent infringement. However, rigid enforcement of patent rights without any exception for research activities may hinder basic science research as well as socially useful follow-on innovation in any given industry. In some cases, the absence of a research exception may give the pioneer patent holder a de facto patent term extension as his competitors will not be able to engage in the pre-market R&D often required to create a saleable product that can be brought to market as soon as the pioneer patent expires. This is most apparent in the case of pharmaceutical regulatory regimes where generic or follow-on drug manufacturers cannot even begin research to satisfy a regulatory agency’s approval process until the pioneer patent expires: the pioneer manufacturer then gets a de facto patent term extension for the time it takes the generic manufacturer to obtain regulatory approval to market its version of the drug. Even outside of this scenario, pioneer patents often give their holders a substantial head start in the...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.